ArticlePloS one2025
Use of machine learning for early prediction of short-term mortality in veterans with metabolic dysfunction-associated steatotic liver disease.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide and affects >25% in the United States population. We hypothesized that clinical features present in electronic health records (EHR) could be extracted early to characterize patients with MASLD who are at high risk of early mortality and that machine learning models would predict mortality better than noninvasive assessments of liver disease/fibrosis.
methodsUsing previously published criteria for MASLD, applied to data from the US Veterans Affairs EHR, we identified a cohort of 13,071 patients between 2000 and 2018 who had an initial diagnosis of MASLD without clinical evidence of cirrhosis. We subsequently used machine-learning and conducted analysis of variance and logistic regression to identify clinical variables to characterize cirrhosis risk and predict mortality within the ensuing 5-years.
resultsThe average age of the cohort was 60 years, had a BMI of 31, and 34% diabetes prevalence. Patients who progressed to cirrhosis were younger when first diagnosed with MASLD (56), had a higher BMI (33), and had significantly higher noninvasive fibrosis scores. Having diabetes at index MASLD diagnosis significantly increased the risk of developing cirrhosis and doubled the risk cirrhosis plus HCC (2.09 CI:1.217-3.63). Our machine-learning model performed significantly better than FIB-4 at predicting mortality within 5-years of being diagnosed with MASLD (AUC 83% vs 68%).
conclusionOur data suggest that machine learning models based on data extracted from the EHR early during MASLD can identify patients likely to develop cirrhosis and predict short term mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.